2 citations
,
May 2024 in “The World Journal of Men s Health” Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.
Long-term, low-dose finasteride may reduce the risk of benign prostatic hyperplasia and prostate cancer.
January 2020 in “Journal of Men s Health” The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
Adherence to finasteride treatment for prostate issues is generally low.
January 2005 in “Metas de Enfermería” Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.
January 2004 in “Actualidad en farmacología y terapéutica” Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.